Alteplase for acute stroke revisited: the first 10 years

[1]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[2]  L Bozzao,et al.  Acute stroke: usefulness of early CT findings before thrombolytic therapy. , 1997, Radiology.

[3]  J. Grotta.  Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA--the best current option for most patients. , 1997, The New England journal of medicine.

[4]  M Frankel,et al.  Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke , 1998, Neurology.

[5]  J. Grotta,et al.  Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. , 1999, Stroke.

[6]  S. Fagan,et al.  Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. , 1999, Neurology.

[7]  J. Grotta,et al.  Early stroke treatment associated with better outcome: the ninds rt-pa stroke study , 2000, Neurology.

[8]  J. Broderick,et al.  Combined Intravenous and Intra-Arterial Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke , 2000, Stroke.

[9]  G. Donnan,et al.  Early CT Changes Do Not Predict Parenchymal Haemorrhage Following Streptokinase Therapy In Acute Stroke. , 2000 .

[10]  A. Demchuk,et al.  Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. , 2001 .

[11]  J. Grotta,et al.  Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. , 2001, JAMA.

[12]  G. D. Graham,et al.  Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice: A Meta-Analysis of Safety Data , 2003, Stroke.

[13]  Joanna M. Wardlaw,et al.  Cost-Effectiveness of Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke Assessed by a Model Based on UK NHS Costs , 2004, Stroke.

[14]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[15]  J. Saver,et al.  Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. , 2004, Archives of neurology.

[16]  P. Lyden,et al.  A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke , 2005, Stroke.

[17]  G. Donnan,et al.  Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging , 2005, Current opinion in neurology.

[18]  S. Warach,et al.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.

[19]  Eric E. Smith,et al.  Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke , 2005, Stroke.

[20]  P. Sandercock,et al.  Alteplase and ischaemic stroke: have new reviews of old data helped? , 2005, The Lancet Neurology.

[21]  J. Grotta,et al.  NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.

[22]  S. Mayer,et al.  Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage , 2007, Stroke.